Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
Interventions: Vactosertib(TEW-7197)/ Durvalumab; Drug
Lead sponsor: MedPacto, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Buffalo, New York

Conditions: Hepatic Impairment
Interventions: Mitiperstat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Rialto, California • Hialeah, Florida • Orlando, Florida + 2 more

Conditions: Atrial Fibrillation
Interventions: dapagliflozin, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Portland, Maine • Detroit, Michigan • Rochester, New York

Conditions: Bullous Pemphigoid
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Centennial, Colorado + 3 more

Conditions: Urothelial Cancer
Interventions: durvalumab, Radiation Therapy; Drug · Radiation
Lead sponsor: Monika Joshi, MD; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Iowa City, Iowa • Omaha, Nebraska • New Brunswick, New Jersey + 4 more

Conditions: Corona Virus Disease
Interventions: AZD7442, AZD8895 (clonal cell line material), AZD1061 (clonal cell line material), AZD8895 (cell pool material), AZD1061 (cell pool material); Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 11 more

Conditions: Asthma
Interventions: Benralizumab-exposure, Exposure to other asthma medications; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab; Biological · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Buffalo, New York • New York, New York

Conditions: Heart Failure, Chronic Kidney Disease
Interventions: AZD9977, Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 130 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 26
States / cities: Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more

Conditions: Opioid Use Disorder
Interventions: Morphine, AZD4041, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Ovarian Cancer, Fatigue, Coping Behavior, Coping Skills
Interventions: Enhanced Usual Care (EOC), REVITALIZE ACT Intervention; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Saracatinab, Placebo; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 40 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Denver, Colorado • New Haven, Connecticut • New York, New York + 1 more

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Benralizumab Pregnancy Exposure Study

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue

Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

About this AstraZeneca sponsor directory page